Beijing Business Daily (Reporter Yao Qian) On March 16, Junshi Bio announced that recently, the company’s holding subsidiary Juntuo Bio and Suzhou Wangshan Wangshui The co-developed oral nucleoside anti-SARS-CoV2 drug VV116 tablets has launched an international multi-center, randomized, double-blind, multi-center, randomized, double-blind, international evaluation of the efficacy and safety of VV116 versus standard therapy in subjects with moderate to severe novel coronavirus pneumonia. Controlled Phase III clinical study, and the first patient enrollment and administration have been completed. Due to the long R&D cycle and many approval links, the drug is easily affected by some uncertain factors. The clinical research process, research results and approval results of VV116 all have certain uncertainties.